- 37. (New) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 60.0% identical to a sequence provided in claim 21, wherein percent identity is calculated using a CLUSTALW global sequence alignment.
- 38. (New) The isolated polynucleotide of claim 37 wherein said nucleic acid sequence further comprises a heterologous nucleic acid sequence.
- 39. (New) The isolated polynucleotide of claim 38 wherein said heterologous nucleic acid sequence encodes a heterologous polypeptide.
- 40. (New) The isolated polynucleotide of claim 39 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

REMARKS

In the Specification:

The paragraph beginning on line 14 of page 1 was amended to make the Field of Invention paragraph consonant with the "Abstract Of The Disclosure" and the remainder of the specification by appending a reference to "K+betaM5". Respectfully, no new matter has been added.

Table I beginning on line 21 of page 70 was amended to correct the "Total AA of ORF" of K+betaM4 from "350" to "351". Support for this amendment may be found in the specification and Figures as originally filed, and in the Sequence Listing as originally submitted. Specifically, support may be found in Figures 1A-B, and in SEQ ID NO:1 and 2 of the Sequence Listing. Respectfully, no new matter has been added.

Marked copies of each paragraph delineating each amendment are submitted herewith in the document entitled, "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

In the Claims:

Claims 1 to 19 have been cancelled and new claims 21 to 40 have been added. Support for the newly added claims may be found in the application as originally filed.

Specifically, support for new claims 21 to 29, in Figures 6A-C, Table I, pages 47-68, 156, 159, original claims 1, 5, 14, and 18, the Sequence Listing, and throughout the application as originally filed. Support for new claims 30 to 33 may be found in original claims 3, 4, 9, 12, and throughout the application as originally filed. Support for new claim 34 to 36, and 38 to 40, may be found on pages 101, 164 to 168, Example 18, and throughout the application as originally filed. No new matter has been added. Support for newly added claim 37 may be found on pages 77 to 89, page

100 to 103, and throughout the application as originally filed. Applicants believe that all of the pending claims before the Examiner are in condition for allowance. An early Office Action to that effect is, therefore, earnestly solicited.

If any fee is due in connection herewith not already accounted for, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: 1-16-03

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

On page 1, replace the Field Of Invention section paragraph beginning on line 14 with the following paragraph:

The present invention provides novel polynucleotides encoding K+betaM4 [or K+betaM5] polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+betaM4 [or K+betaM5] polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.--

On page 70, replace Table I beginning on line 21 with the following new Table I:

-- <u>Table I</u>

Gene	CDNA	ATCC	Vector	NT	Total	5' NT	3' NT	AA Seq	Total
No.	CloneID	Deposit		SEQ	NT Seq	of Start	of	ID No.	AA of
		No. Z and		ID.	of	Codon	ORF	Y	ORF
		Date		No. X	Clone	of ORF			
1.	K+betaM4	XXXXX	Psport1	1	1839	5	1057	2	350[1]
	(2BAC-	xx/xx/xx							
}	18)	,				į			
2.	K+betaM5	XXXXX	Psport1	23	2154	1	1029	24	343
	(2BAC-3)	xx/xx/xx							